2025
P-551. The Effects of Antiretroviral Therapy on Immune Activation, Inflammation, Cellular Changes and Clinical Outcomes in Elite Controllers
Chan E, Zhou L, Emu B, Paintsil E, Barakat L. P-551. The Effects of Antiretroviral Therapy on Immune Activation, Inflammation, Cellular Changes and Clinical Outcomes in Elite Controllers. Open Forum Infectious Diseases 2025, 12: ofae631.750. PMCID: PMC11777457, DOI: 10.1093/ofid/ofae631.750.Peer-Reviewed Original ResearchEffects of antiretroviral therapyAntiretroviral therapyElite controllersViral loadIL-6Inflammatory markersImmune activationReactive oxygen speciesReactive oxygen species productionAdverse effects of ARTMitochondrial membrane potentialBenefits of antiretroviral therapyAntiretroviral Therapy ToxicitiesInflammatory markers IL-6Antiretroviral therapy groupHIV viral loadMembrane potentialCurrent published dataUtilization of antiretroviral therapyCellular inflammatory markersCompared to baselineViremic controllersClinical outcomesCRP decreaseLevels of mtDNA deletions
2023
Pediatric HIV Disclosure Intervention Improves Immunologic Outcome at 48 Weeks: The Sankofa Trial Experience
Shabanova V, Emuren L, Gan G, Antwi S, Renner L, Amissah K, Kusah J, Lartey M, Reynolds N, Paintsil E. Pediatric HIV Disclosure Intervention Improves Immunologic Outcome at 48 Weeks: The Sankofa Trial Experience. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 94: 371-380. PMID: 37643414, PMCID: PMC10617661, DOI: 10.1097/qai.0000000000003292.Peer-Reviewed Original ResearchConceptsHIV disclosure interventionsVirologic outcomesCD4 percentWeek 48HIV statusIntervention groupHIV disclosureDisclosure interventionDetectable viral loadWorld Health OrganizationAntiretroviral therapyImmunologic outcomesClinical outcomesIntervention armViral loadControl armClinical trialsTrial experienceSecondary analysisDisclosure statusHealth OrganizationCategorical variablesWeeksLinear mixed modelsBaseline
2018
2247. Antiretrovirals Perturb Cholesterol Biosynthesis in PBMCs of HIV-Infected Individuals
Sopeyin A, Li M, Paintsil E. 2247. Antiretrovirals Perturb Cholesterol Biosynthesis in PBMCs of HIV-Infected Individuals. Open Forum Infectious Diseases 2018, 5: s664-s665. PMCID: PMC6252475, DOI: 10.1093/ofid/ofy210.1900.Peer-Reviewed Original ResearchAntiretroviral therapyMetabolic syndromeTenofovir/emtricitabine/efavirenzEffect of ARTHispanic whitesCholesterol biosynthesisZidovudine/lamivudineCase-control studyLow-density lipoprotein receptorSterol regulatory element-binding protein 2Non-Hispanic whitesDensity lipoprotein receptorRace/ethnicityAge of participantsART regimenWilcoxon rank testMetabolic derangementsViral loadHealthy controlsCardiovascular diseaseCopies/High prevalenceTherapeutic benefitSide effectsLipoprotein receptor
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply